ten23 health

ten23 health is a CDMO that supports its clients in developing differentiated, stable, usable and safe injectables, and has specialist experience in the sterile filling of complex pharmaceuticals into innovative containers and devices.

Headquarters
ten23 health AG
Mattenstrasse 22
4058 Basel
Switzerland

Phone / Contact

E: [email protected]

Connect

ten23 health is a pharmaceutical CDMO that supports its clients in developing differentiated, stable, usable and safe injectable treatment options for patients. The company combines the latest scientific findings with proven industry and regulatory expertise to forge new paths for its clients’ needs.

ten23 provides its innovative services in a fair and sustainable manner, respecting people’s health and the future of the planet.

In 2021, ten23 acquired and subsequently fully integrated swissfillon, a specialist in the sterile filling of complex pharmaceuticals into innovative containers and devices.

Regarding the company’s name: the numeric value for the number of molecules in a sample of 1 mol is called Avogadro’s constant and equals 6.022 x 1023. Gramme quantities of material contain the incredible number of 1023 atoms, which was an important discovery in the understanding of the composition of matter: the world is built from small units and not a homogeneous mass.

Articles by ten23 health

Dr Andrea Allmendinger

TECHNICAL CHALLENGES DURING THE DEVELOPMENT OF ON-BODY INJECTORS

Andrea Allmendinger, Michael Adler, Carole Delauney and Hanns-Christian Mahler provide an overview of large-volume wearable injection devices for the subcutaneous delivery of biologics and discuss the technical challenges associated with the development and manufacturing of these drug/device combination products.

Dr Michael Adler

TRANSITIONING FROM VIAL TO SUBCUTANEOUS INJECTION DEVICES FOR BIOLOGICAL DRUG PRODUCTS

Michael Adler, Venkata Appa Reddy Goli, Andrea Allmendinger and Hanns-Christian Mahler, discuss the various factors that need to be considered when transferring to a delivery device for subcutaneous injection, such as a prefilled syringe or autoinjector, during clinical trials or post-launch, especially when transferring from a vial format for intravenous infusion.

LEVERAGING AI & BIG DATA FOR ECO-DESIGN COLLABORATION IN PHARMA

Alissa Monk, Kami Krista, Cédric Montagnetegy and Carole Schanté, explore the potential of artificial intelligence and big data in eco-design with the aim of transforming the pharmaceutical industry towards greater sustainability.

Dr Andrea Allmendinger

ADDRESSING INTRAVITREAL PRODUCT MANUFACTURING AND DEVELOPMENT CHALLENGES

Andrea Allmendinger, Hanns-Christian Mahler and Philipp Behrendt discuss the challenges of filling very small volumes into syringes for intravitreal injections, and how ten23’s innovative filling technology can help combat the critical issue of air bubble formation.

INDUSTRIALISATION

Dr Andrea Allmendinger

INTEGRATED DRUG PRODUCT DEVELOPMENT AND MANUFACTURING

Andrea Allmendinger; Michael Adler and Hanns-Christian Mahler highlight the importance of integrated drug product development, considering aspects such as formulation, device, container closure system, manufacturing processes and usability, as well as considering the quality target product profile and clinical phase-appropriate technical development strategy.

Dr Andrea Allmendinger

INTRAVITREAL INJECTIONS – MORE THAN MEETS THE EYE: A TECHNICAL VIEW OF PRODUCT USE

Andrea Allmendinger and Hanns-Christian Mahler highlight the technical challenges of intravitreal administration and considerations from the ophthalmologist’s and patient’s perspectives.

PREFILLED SYRINGES

Dr Andrea Allmendinger

ANTICIPATING & MITIGATING CHALLENGES IN THE COMMERCIALISATION OF PREFILLED SYRINGES & INJECTION DEVICES – A TECHNICAL DRUG PRODUCT PERSPECTIVE

Andrea Allmendinger and Hanns-Christian Mahler both at ten23 health, provide an insight into the challenges of integrated development of drug product and device design and fill-finish manufacturing operations.

Dr Andrea Allmendinger

HOW TEN23 HEALTH IS MEETING DEVELOPMENTAL CHALLENGES FOR INTRAVITREAL PRODUCTS

Andrea Allmendinger and Hanns-Christian Mahler highlight new regulatory and quality requirements for intravitreal applications and discuss technical challenges during drug product technical development and manufacturing.

Rainer Glockler

OPHTHALMIC DRUGS: PATHWAY TO OVERCOME PRIMARY PACKAGING AND DRUG PRODUCT MANUFACTURING CHALLENGES

Rainer Glöckler, Carole Delauney, Dr Nicolas Eon and Katsuyuki Takeuchi discuss the myriad complexities of developing drug products for intravitreal injection, and how the partnership between swissfillon and Terumo can ease and accelerate these products to market. The first article, published in April, covered how swissfillon’s state-of-the-art filling line meets the complex requirements of ophthalmic drug products.

Rainer Glockler

STATE-OF-THE-ART SOLUTIONS FOR OPHTHALMIC STERILE DRUG PRODUCT MANUFACTURING

In the first in a series of two articles, Rainer Glöckler and Carole Delauney discuss how the company’s state-of-the-art filling line meets the requirements and complexities that are particular to ophthalmic drug product manufacturing. The second article, to be published in May, will explore partnerships between pharma, CDMOs and syringe manufacturers in more detail.

Top